Okay besties, let’s talk about a biotech stock that’s been quietly winning while everyone’s distracted by the shiny AI names.
Vertex Pharmaceuticals (VRTX) has outperformed the broader market over the past five years — which is honestly impressive for a company that half of Wall Street loves to side-eye. The skeptics point to one big issue: Vertex isn’t diversified. Its entire empire is built on cystic fibrosis (CF) drugs, and its attempts to launch products beyond that core area have been, well, a mixed bag. Some investors worry that means subpar returns over the next five years.
Here’s my take: I don’t buy the fear. In fact, I think Vertex could be one of the best biotech stocks to own through 2031. Let me break down why — because this is exactly the kind of “understand the business before you buy” analysis I coach my clients through.
The core business is still crushing it
Vertex is the undisputed queen of the CF drug market — think of it like owning the only coffee shop in a city of caffeine addicts. Its CF products pulled in $3.3 billion of its $3.44 billion in third-quarter revenue, which grew 12% year over year.
Its star product, Trikafta (approved back in 2019), is still the top seller. But here’s a fun passing-of-the-torch moment: the newer Alyftrek, with a more convenient once-daily dose, is winning over Trikafta patients. Alyftrek’s Q3 sales jumped almost 186% year over year to $705.8 million, while Trikafta’s slipped 8% to $2.4 billion. That’s not a problem — that’s Vertex upgrading its own customers.
And the competition threat? Basically took a nap. Sionna Therapeutics, a CF-focused biotech, announced its leading candidate flopped in a Phase 2a trial earlier this year. Here’s what I’d tell my coaching clients: when your biggest rival stumbles AND your patent protection runs through the late 2030s, you’ve got a long runway. Trikafta and Alyftrek don’t face patent cliffs for the next five years.
The “diversification” story is starting to pay off
Now, the skeptics aren’t entirely wrong — Vertex needed new growth engines. But the pipeline is finally showing life.
First up: Casgevy, a gene-editing medicine for sickle cell disease and transfusion-dependent beta-thalassemia. Its Q3 sales grew almost 487% year over year to $99.2 million. Yes, it’s still small, but this is what an inflection point looks like. Casgevy is pricey ($2.2 million per treatment course in the U.S.) and complicated to administer, which is why Vertex and its partner CRISPR Therapeutics have spent the past few years since the 2023 approval getting insurers on board and building out treatment centers. Think of it like building the infrastructure before the grand opening — slow, unglamorous, but essential.
Then in July, Casgevy got a U.S. label expansion to treat patients as young as two, adding 5,500 people to its addressable market. At $2.2 million a pop, that’s a meaningful expansion. Meanwhile, Journavx, Vertex’s drug for acute pain, is playing in a market hungry for non-opioid options — and that need isn’t going anywhere.
The spending could absolutely pay off
Vertex isn’t slowing down on investment, and I love a company that knows how to put its money to work. The FDA could approve povetacicept — a potential treatment for IgA nephropathy, a kidney disease — by the end of this month, with possible label expansions to come. Add inaxaplin (Phase 3 for APOL1-mediated kidney disease) and VX-407 (Phase 2 for polycystic kidney disease), and you’ve got a legit kidney disease franchise brewing.
And in September, Vertex closed a $10 billion acquisition of Crinetics Pharmaceuticals, a specialist in endocrine diseases. That deal brought in Palsonify, an approved drug for acromegaly — a rare disease causing excess growth hormone and enlarged bones that can be fatal if untreated — plus atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia.
This is why I tell my coaching clients: a deep pipeline plus a money-making product lineup is the biotech version of having a stable salary AND side hustles. Multiple streams, one powerful portfolio. Between internal candidates and the acquisition, Vertex should keep landing new approvals over the next few years — on top of a lineup that’s already performing beautifully.
My honest take
Is Vertex risky? Every single stock is, bestie. But the bears are betting on a decline in its only growth driver, and the evidence says otherwise: patent protection into the late 2030s, a squashed challenger, new products ramping, and a pipeline that’s finally diversifying. That’s not a company in trouble — that’s a company in transition, and transitions are often where patient investors get rewarded.
You don’t need to be a biotech expert to invest like one. You just need to look past the headlines and read the fundamentals — and now you know how to do exactly that.
If this breakdown helped you feel more confident about evaluating stocks, come hang out with me — DM me your biggest investing question or join my mailing list so you never miss a money moment. Let’s build your wealth on your terms, one smart move at a time. 💛
